# COMPANY FACT SHEET

**INOVIQ (ASX: IIQ) is developing diagnostic and exosome-based solutions for cancer and other diseases to enable earlier and more accurate detection to improve treatment options, patient outcomes and overall survival.**

## Investment highlights

- Proprietary technology platforms for biomarker isolation and detection
- Products in-market for bladder cancer & exosome research
- Multi-product pipeline for detection and monitoring of breast, ovarian and other cancers targeting US$15b global markets
- Compelling early data in breast and ovarian cancers
- Multiple key inflection points over next 12 months
- Experienced management team with track record in healthcare leadership, diagnostic development and commercialisation
- Strong cash position fund operations and pipeline development

## Market need and commercial opportunity

- Focused on unmet needs for non-invasive, accurate and reliable diagnostic tests for earlier detection of cancer (and other diseases)
- Cancers are often diagnosed at late-stage after symptoms have appeared, resulting in poor prognosis.
- INOVIQ's technologies enable earlier and more accurate detection - improving treatment and patient survival[1]

**5-year survival rates by stage at diagnosis[1]**




## Global cancer diagnostics market

Global cancer diagnostics market valued at **US$250b**[2]. INOVIQ is currently targeting markets worth over **US$15b** for some of the world's most common and deadliest cancers.


| Market data | |
|---|---|
| ASX code: | I!Q |
| Share price: | $0.51* |
| Market cap: | $46.93m* |
| Shares on issue: | 92,018,702* |
| Cash at bank: | $17.3m as at 31 March 2022 |

| Board and management | |
|---|---|
| Dr Geoff Cumming PhD | Non-Executive Chairman |
| Mr Max Johnston | Non-Executive Chairman |
| Mr Philip Powell | Non-Executive Director |
| Prof Allan Cripps AO PhD | Non-Executive Director |
| Dr Leearne Hinch | Chief Executive Officer |
| Dr Greg Rice PhD | Chief Scientific Officer |
| Mr Tony Di Pietro | CFO & Company Secretary |
| Dr Rocco Iannello | BD / Licensing Director |

**Contacts**


Dr Leearne Hinch | CEO
lhinch@inoviq.com
+61 400 414 416

Dr Rocco Iannello
riannello@inoviq.com
+61 408 547 394

Jane Lowe | Investor Relations
Jane.lowe@irdepartment.com.au
+61 411 117 774


*1 SEER 18 2010-2016;* 2 Grand View Research 2019. https://www.grandviewresearch.com/press-release/global-cancer-diagnostics-market, * As at 13 May 2022

# COMPANY FACT SHEET

## Recent collaborations and partnerships for IIQ's diagnostic pipeline

- Collaboration with University of Queensland (AUS) to develop world-first exosome-based ovarian cancer screening test
- Master Services Agreement with US-based specialty contract diagnostics organisation ResearchDx to undertake development and validation of SubB2M-based tests
- Master Manufacturing Agreement with MP Biomedicals for production of the SubB2M protein for the Company's SubB2M-based tests

## Our products and pipeline

| PRODUCT | INDICATION | PLATFORM | USE | RESEARCH | ASSAY DEVELOPMENT | CLINICAL DEVELOPMENT | REGISTRATION |
|---|---|---|---|---|---|---|---|
| hTERT[1] | Bladder Cancer | ICC | Adjunct to cytology | | | | ★ In-market |
| EXO-NET-RUO | Exosome Capture | Device | Research tool | | | | ★ In-market |
| Exosome-OC[3] (OCRF-7) | Ovarian Cancer | Multiomic | Screening | | | | |
| SubB2M-BCM | Breast Cancer | Immunoassay | Monitoring | | | | 2023 |
| SubB2M-OCM | Ovarian Cancer | Immunoassay | Monitoring | | | | 2023 |
| SubB2M-PCS | Prostate Cancer | Immunoassay | Detection | | | | |
| SubB2M-PaC | Pancreatic Cancer | Immunoassay | Detection | | | | |
| BARD1-Ovarian[2] | Ovarian Cancer | Immunoassay | Detection | | | | |
| BARD1-Breast[2] | Breast Cancer | Immunoassay | Detection | | | | |
| BARD1-Lung[2] | Lung Cancer | Immunoassay | Detection | | | | |

**RUO = Research Use Only; ICC = Immunocytochemistry;*

*1. Adjunct to urine cytology to assist the detection of bladder cancer; 2. Progression subject to completion of review (ASX: 28/3/22) ; 3 Umbrella Research & Option Agreement with UQ*

## Our proprietary technologies and products

### SubB2M

**Highly specific probe that detects the pan-cancer marker Neu5Gc found in multiple human cancers.**

Applications for **pan-cancer detection and monitoring** to improve performance of existing cancer biomarker tests.

Feasibility data showing a SubB2M-based SPR test detects breast and ovarian cancers across all stages with over 95% sensitivity and 100% specificity.

### NETs

**NETs platform enables the capture of target analytes from any biofluid.**

Initial applications enabling **exosome isolation, biomarker discovery and diagnostics**.

EXO-NET® research tools available in-market to capture exosomes with speed, purity and yield advantages.


### BARD1

**Biomarker technology covering various BARD1 tumour markers and methods of use for diagnostic applications.**

Applications for **earlier cancer detection**.

Feasibility data showing high accuracy of BARD1 autoantibody tests to detect ovarian, breast and lung cancers.

### HTERT

**Anti-hTERT antibody technology that detects hTERT that is upregulated in various human cancers.[1]**

Applications in **immunocytochemistry** (ICC).

hTERT ICC test available in-market as an adjunct to urine cytology to assist the diagnosis of bladder cancer.